Fujifilm Misses on Earnings by a Cent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 1:30PM CDT
Fujifilm (FUJIY) missed the Zacks Consensus Estimate for earnings in the fourth quarter of fiscal 2014 by a cent.
A Closer Look at the All-New 2015 Subaru Outback
John Rosevear and Rex Moore, The Motley Fool - Motley Fool - Tue Apr 29, 12:15PM CDT
Subaru U.S. chief Thomas Doll and Fuji Heavy Industries CEO Yasuyuki Yoshinaga presented the all-new 2015 Subaru Outback to the media in New York. Photo credit: Subaru The New York International Auto Show is a major stop on the world's auto show...
General Motors Company Hunkers Down in New York
John Rosevear and Rex Moore, The Motley Fool - Motley Fool - Sun Apr 20, 7:00AM CDT
The main floor of the New York International Auto Show was loud and crowded on Wednesday. But GM's stands, off in a separate wing, were relatively quiet. Photo credit: Rex Moore/The Motley Fool. Walking around the New York International Auto Show...
Photronics, Dai Nippon Printing Form JV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 1:10PM CDT
Photronics and Dai Nippon Printing completed the previously announced joint venture.
Global Mammography Equipment Market 2014-2018 with FUJIFILM, GE Healthcare, Hologic, Phillips Healthcare & Siemens Healthcare Dominating
M2 - Fri Apr 04, 5:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g7fhk2/global) has announced the addition of the "Global Mammography Equipment Market 2014-2018 with FUJIFILM, GE Healthcare, Hologic, Phillips Healthcare & Siemens Healthcare Dominating" report to their offering. One of the main drivers in this market is the increasing incidence of breast cancer among women which has led to an increase in the demand for mammography equipment for the accurate diagnosis of breast cancer. Commenting on the report, an analyst from the team said: With technological advancements, there has been an increase in the use of 3D mammography globally in recent years. The 3D mammography system is considered to be 7 percent more accurate compared to the traditional 2D mammography system. The 3D mammography system is currently available for commercial use in Latin America, Europe, and Asia. There is currently only one product available though, which is Selenia Dimensions 3D tomosynthesis offered by Hologic Inc. It was approved for sale in the US by the FDA on February 11, 2011 and has generated the maximum revenue for Hologic Inc. in the US. The introduction of new generation mammography equipment has enhanced the efficiency of breast cancer surgeries and treatments. 3D mammography removes overlapping tissue artifacts, especially in dense breasts and offers better screening sensitivity. Thus, the growing use of 3D mammography is expected to drive growth in the Global Mammography Equipment market. Further, the report states that one of the major challenges in the market is the high cost of mammography equipment which is hampering its adoption and installation in hospitals worldwide. Key vendors dominating this space are: - FUJIFILM Holdings Corp. - GE Healthcare - Hologic Inc - Phillips Healthcare - Siemens Healthcare. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type 08. Rate of Incidence and Prevalence 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape For more information visit http://www.researchandmarkets.com/research/g7fhk2/global
FUJIFILM Supports Warrior Hike as New Sponsor
Business Wire - Wed Apr 02, 9:28AM CDT
FUJIFILM Holdings America Corporation is delighted to announce its sponsorship of Warrior Hike, a non-profit organization supporting combat veterans transitioning from their military service by hiking America's National Scenic Trails.
Melvin: Keep It Simple
at The Street - Fri Mar 21, 2:30PM CDT
You only need to ask these two questions when selecting a stock.
Risk-Wary Investors Deal Nippon Stocks A Harsh Blow
at Investor's Business Daily - Fri Mar 14, 4:42PM CDT
While U.S. markets lodged a disappointing week, markets overseas put in some of the worst performances in a year. The Tokyo Stock Exchange was hardest hit among those, with the Nikkei 225 tumbling 3.3% Friday -- leaving the index down 6.2% in its...
Updated Research Report on Fujifilm - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 6:15PM CST
On Feb 27, 2014, we issued an updated research report on Fujifilm Holdings Corporation.
Sanofi's CEO Admits Lackluster Drug Development Decade but Defends Its Pipeline: Sanofi (OTCQB: SNYNF), Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Feb 10, 10:12AM CST
The fierce competition coming from generic drug companies, the escalating costs of developing new drugs and the arduous process of getting them approved weighs heavily on Sanofi (OTCQB: SNYNF) and its competitors.
Fujifilm's Q3 Earnings Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 1:00PM CST
Fujifilm reports improved year-over-year results in the third quarter of fiscal 2014.
Federal Court Ruling Could Be Set Back for Royal Dutch Shell Stock: Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Sanofi (OTCQB: SNYNF), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Jan 27, 2:01PM CST
Whether a recent federal court ruling will scrap Royal Dutch Shell Plc (OTCQB: RYDAF) Alaska drilling plans remains to be seen, but the uncertainty it creates could affect the oil company's share price.
Global Mammography Equipment Market 2014-2018: Market Witnessing the Growing use of 3D Mammography
M2 - Thu Jan 16, 5:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/pq3pxr/global) has announced the addition of the "Global Mammography Equipment Market 2014-2018" report to their offering. The analysts forecast the Global Mammography Equipment market to grow at a CAGR of 9.84 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of breast cancer. The Global Mammography Equipment Market 2014-2018 has also been witnessing the growing use of 3D mammography. However, the high cost of mammography equipment could pose a challenge to the growth of this market. Key vendors dominating this space are FUJIFILM Holdings Corp., GE Healthcare, Hologic Inc., Phillips Healthcare, and Siemens Healthcare. Other vendors mentioned in the report are Carestream Health Inc., Internazionale Medico Scientifica Srl, PerkinElmer Inc., Planmed Oy and Toshiba Medical Systems Corp. Commenting on the report, an analyst from the team said: With technological advancements, there has been an increase in the use of 3D mammography globally in recent years. The 3D mammography system is considered to be 7 percent more accurate compared to the traditional 2D mammography system. The 3D mammography system is currently available for commercial use in Latin America, Europe, and Asia. There is currently only one product available though, which is Selenia Dimensions 3D tomosynthesis offered by Hologic Inc. It was approved for sale in the US by the FDA on February 11, 2011 and has generated the maximum revenue for Hologic Inc. in the US. The introduction of new generation mammography equipment has enhanced the efficiency of breast cancer surgeries and treatments. 3D mammography removes overlapping tissue artifacts, especially in dense breasts and offers better screening sensitivity. Thus, the growing use of 3D mammography is expected to drive growth in the Global Mammography Equipment market. According to the report, the Global Mammography Equipment market is driven by several factors. One of the main drivers in this market is the increasing incidence of breast cancer among women which has led to an increase in the demand for mammography equipment for the accurate diagnosis of breast cancer. For more information visit http://www.researchandmarkets.com/research/pq3pxr/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Fujifilm Eyes Growth Through Portfolio Boost - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 5:30PM CST
Fujifilm Holdings has been attempting to grow with product launches.
Pipeline Progress at Cempra - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 4:00PM CST
Cempra recently initiated a phase III trial on antibiotic candidate, solithromycin.
Global Small Animal Imaging Market Report 2013-2017
PR Newswire Europe - Wed Dec 11, 12:11PM CST
DUBLIN, Dec. 11, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/94fx8f/small_animal [http://www.researchandmarkets.com/research/94fx8f/small_animal]) has announced the addition of the "Global Small Animal Imaging Market Report 2013-2017" [http://www.researchandmarkets.com/research/94fx8f/small_animal] report to their offering.
Fujifilm Sets Up Myanmar Subsidiary - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 29, 4:55PM CST
Fujifilm recently announced the set-up of a new subsidiary in Myanmar, Fujifilm Myanmar Limited.
Hewlett-Packard (HPQ) Catches Eye: Stock Jumps 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 29, 7:11AM CST
Hewlett-Packard (HPQ) was a big mover last session, as the company saw its shares rise by a little above 9% on the day.
Fujifilm Downgraded to Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 16, 11:50AM CDT
On Sep 13, 2013, we downgraded our recommendation on Fujifilm Holdings Corporation to Neutral from Outperform.
Data on Cempra's Solithromycin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 06, 3:25PM CDT
Cempra, Inc. announced that solithromycin, showed safety and tolerability in patients.